Daiichi Sankyo
Greg Khvalabov, PACS, has extensive experience in the pharmaceutical and oncology fields, currently serving as Senior Associate Director and Field Trainer in Field Reimbursement at Daiichi Sankyo, Inc. since March 2019. Prior to this role, Greg held the position of Sr. Manager for Reimbursement Services and Operations focused on Oncology Biosimilars at Pfizer from August 2018 to March 2019. Between October 2014 and August 2018, Greg was the Associate Director for Strategic Market Access in Cellular Therapy CAR-T at Novartis Oncology. Earlier in Greg's career, significant roles included Associate Director of Federal and State Government Relations and National Account Manager at BD, Market Access Manager at Cancer Treatment Centers of America, and Pharmaceutical Sales Representative at Roche.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.